Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

Dementia biomarkers -- phosphorylated tau (P-tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) - ...

A new study reveals that cognitive changes tied to Alzheimer's risk factors begin far earlier in life than previously thought, some as early as age 24.

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

A one-year prospective study found no correlation between atherosclerosis and extremely high cholesterol levels in 100 ...

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat ...